Badanie nad skutecznością i bezpieczeństwem axatilimabu i ruxolitinibu u pacjentów z przewlekłą chorobą przeszczep przeciwko gospodarzowi

Chronic Graft-Versus-Host Disease (cGVHD) is a condition that can occur after a bone marrow transplant, where the donated cells attack the recipient's body. This study is focused on evaluating the safety and effectiveness of a treatment combining two medications: Axatilimab and ruxolitinib. Axatilimab is given as a solution for infusion, which means it is administered directly into the bloodstream, while ruxolitinib is taken in tablet form. The purpose of the study is to see how well these medications work together in treating newly diagnosed cases of cGVHD.

Participants in the study will receive either the combination of axatilimab and ruxolitinib or a different treatment, which may include medications like prednisone or methylprednisolone, both of which are steroids. The study will monitor the participants over a period of time to assess the response to the treatment and any side effects. The goal is to determine if the combination of axatilimab and ruxolitinib provides a better outcome for patients with cGVHD compared to other treatments.

The study is designed to be open-label, meaning both the researchers and participants know which treatment is being administered. It will take place in multiple centers, allowing for a diverse group of participants. The effectiveness of the treatment will be evaluated at different points, such as six months and twelve months, to see how well the disease is being managed. Safety will also be closely monitored to ensure the well-being of all participants throughout the study.